Xencor Inc
corporate_fare Company Profile
Xencor Inc (NASDAQ:XNCR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for XNCR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 11 rated 8 or above. Recent SEC coverage for XNCR spans 10-Q, 8-K, DEFA14A, DEF 14A.
Recent high-impact activity:
- Xencor 10-Q: Q3 Swings to $39.4M Profit on $116.5M Revenue; $555.7M Cash Funds Operations Into 2029
- Xencor Swings to $39.4M Profit as Royalties and Milestones Lift Revenue 5x
- Analyst Calls XmAb819 Profile 'Unprecedented' as Shares Jump 20% to Near 52-Week High
- Xencor Picks 400 mcg/kg XmAb819 Dose, Targets Phase 3 by End-2027
- Xencor Locks Phase 3 Dose for XmAb819 After 45.5% Response Rate in Kidney Cancer
Financial Snapshot
Short Interest & Short Volume
6.58 days to coverFINRA reported short interest of 12,896,418 shares in XNCR as of the October 30, 2026 settlement, a 5.1% increase from the prior period — about 6.6 days to cover at its recent average daily volume. On November 20, 2026, 72.7% of XNCR volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.